Penn hematologist elected to lead American Society of Hematology
Alison Wakoff Loren, MD, MSCE, to serve as vice president, before taking on presidency of ASH.
Members of the American Society of Hematology (ASH) have elected Alison Wakoff Loren, MD, MSCE, division chief of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, to serve as the incoming vice president of the society. Loren will serve a one-year term as vice president starting after the 2025 ASH Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida, followed by successive terms as president-elect and then leading the organization as president.
With more than 18,000 members from nearly 100 countries, ASH is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
“Hematology impacts every aspect of health, and we have a responsibility as hematologists to honor and advocate for all people with blood diseases,” Loren said. “I look forward to serving the broad hematology community of clinicians and researchers, especially in advancing ASH’s advocacy work and funding for research and career development during times of uncertainty.”
Dedicated to improving the lives of patients with blood cancers
Since completing her internal medicine residency and Hematology-Oncology Fellowship at Penn Medicine, Loren has spent her entire professional career here, stepping up to lead the Hematology-Oncology division in 2022. She is the C. Willard Robinson Professor of Hematology-Oncology and director of Blood and Marrow Transplantation at the Abramson Cancer Center. Her clinical practice focuses on allogeneic bone marrow transplant, and she is deeply committed to improving access to and outcomes of allogeneic hematopoietic cell transplantation and long-term survivorship, including fertility preservation and reproductive health in cancer survivors.
Loren has published more than 130 peer-reviewed manuscripts and is the senior author on the American Society of Clinical Oncology’s Fertility Preservation guidelines. She is a member of the Editorial Board for the Art of Oncology at the Journal of Clinical Oncology and is active in national and international professional groups related to bone marrow transplantation, including nearly 20 years of service to the ASH on a range of committees.
Adam Cuker elected to ASH Executive Committee
Additionally, Adam Cuker, MD, MS, was elected to a four-year term as councillor on the ASH Executive Committee. Cuker is the section chief for Hematology, clinical director of the Penn Blood Disorders Center, director of the Penn Comprehensive and Hemophilia Thrombosis Program, and a professor of Medicine. His clinical expertise is in clotting, bleeding, and platelet disorders. His term will also begin following the 2025 ASH Annual Meeting.